Bio-Techne Corporation (TECH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

35.3x

EV/EBITDA

33.1x

Market Cap

$11.36B

MomentumView details →

1D Return

−0.03%

YTD Return

+23.15%

RSI (14)

64.8

ValuationView details →

P/E (Fwd)

35.3x

EV/EBITDA

33.1x

Market Cap

$11.36B

RSI (14)

64.8

MomentumView details →

1D Return

−0.03%

YTD Return

+23.15%

SummaryUpdated Jun 1, 2026

Bio-Techne Corporation (NASDAQ:TECH) is a Minneapolis-based biotechnology company founded in 1976 that develops, manufactures, and sells life science research tools and diagnostic products worldwide. Originally known as Techne Corporation until 2014, the company has grown through strategic acquisitions and organic expansion to become a leading provider of biological reagents, instruments, and services serving the research and clinical diagnostic markets. Bio-Techne operates through two primary business segments and has established itself as a critical supplier to pharmaceutical companies, biotechnology firms, academic institutions, and clinical laboratories globally.

Ask drillr about Bio-Techne Corporation →

ProfitabilityView details →

Gross Margin

65.77%

Net Margin

14.97%

EBITDA Margin

28.27%

ROE (TTM)

8.63%

ROA (TTM)

7.03%

Asset Turnover

0.47x

GrowthView details →

Revenue YoY

−0.38%

EPS YoY

+154.35%

FCF YoY

+2.60%

Revenue CAGR 3Y

+2.25%

EPS CAGR 3Y

−13.54%

EBITDA YoY

+58.36%

EarningsView details →

EPS (Actual)

$0.52

EPS Surprise

0.19%

Beats (12Q)

6/12

Next Q EPS Est

$0.44

Avg Surprise (4Q)

0.80%

Rev Surprise

2.09%

Capital & dividendView details →

Debt/Equity

0.14x

Current Ratio

4.55x

Quick Ratio

3.35x

Div Yield

0.44%

Div Rate

$0.32

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.22B

Net Income (TTM)

181.86M

Op. CF (TTM)

292.07M

Next earningsNov 4, 2026 →

Latest newsMore news →

BlackRock Inc. disclosed a new stake of 14,025,816 shares in Bio-Techne Corp, valued at approximately $990,924,000, representing about 8.96% ownership, in a recent SEC filing.13d ago

As of August 20, 2026, the total margin trading balance on China's A-share market decreased by 1.248 billion yuan to 2.666356 trillion yuan, with net financing purchases led by Zhongji Innolight at 530 million yuan.15d ago

Similar companies

欧林生物688319.SH Suzhou Ribo Life Science Co06938.HK Mabwell-b02493.HK 诺唯赞688105.SH HBM Holdings Limited02142.HK Duality Biotherapeutics, Inc.09606.HK Find similar companies →

Latest newsMore news →

BlackRock Inc. disclosed a new stake of 14,025,816 shares in Bio-Techne Corp, valued at approximately $990,924,000, representing about 8.96% ownership, in a recent SEC filing.13d ago As of August 20, 2026, the total margin trading balance on China's A-share market decreased by 1.248 billion yuan to 2.666356 trillion yuan, with net financing purchases led by Zhongji Innolight at 530 million yuan.15d ago